Advertisement

Index by Author

November 1999; 48 (11)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Ades, P A

    • Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes November 1999 48:2210-2214; doi:10.2337/diabetes.48.11.2210

  2. Amri, K

    • Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes November 1999 48:2240-2245; doi:10.2337/diabetes.48.11.2240

  3. Arch, J R

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

B

  1. Babu, S

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  2. Bach, L A

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  3. Bektas, A

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

  4. Bellmunt, M J

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

  5. Benito, M

    • Insulin signaling in insulin receptor substrate (IRS)-1-deficient brown adipocytes: requirement of IRS-1 for lipid synthesis. Diabetes November 1999 48:2122-2131; doi:10.2337/diabetes.48.11.2122

  6. Beresford, S

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  7. Bergerot, I

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

  8. Blankenhorn, E P

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  9. Boden, G

    • Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes November 1999 48:2182-2188; doi:10.2337/diabetes.48.11.2182

  10. Bogardus, C

    • Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes November 1999 48:2197-2203; doi:10.2337/diabetes.48.11.2197

  11. Bokvist, K

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

  12. Buckingham, R E

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

C

  1. Cabiscol, E

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

  2. Cai, X J

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  3. Capito, K

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

  4. Casley, D J

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  5. Cester, N

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  6. Chen, X

    • Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes November 1999 48:2182-2188; doi:10.2337/diabetes.48.11.2182

  7. Clapham, J C

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  8. Colman, P G

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  9. Cooke, A

    • Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes November 1999 48:2157-2165; doi:10.2337/diabetes.48.11.2157

  10. Cooper, M E

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  11. Couper, J J

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  12. Cox, A J

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  13. Czerkinsky, C

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

D

  1. DeNino, W F

    • Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes November 1999 48:2210-2214; doi:10.2337/diabetes.48.11.2210

  2. Doria, A

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

  3. Durand, A

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

  4. Dvorak, R V

    • Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes November 1999 48:2210-2214; doi:10.2337/diabetes.48.11.2210

E

  1. Eisenbarth, G S

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

F

  1. Fowell, D J

    • Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes November 1999 48:2157-2165; doi:10.2337/diabetes.48.11.2157

  2. Freund, N

    • Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes November 1999 48:2240-2245; doi:10.2337/diabetes.48.11.2240

  3. Fumelli, D

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

G

  1. Gellert, S

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  2. Giannoukakis, N

    • Targeting autoimmune diabetes with gene therapy. Diabetes November 1999 48:2107-2121; doi:10.2337/diabetes.48.11.2107

  3. Gilbert, R E

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  4. Gilon, P

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

  5. Gottlieb, P A

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  6. Grasso, P

    • Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes November 1999 48:2204-2209; doi:10.2337/diabetes.48.11.2204

  7. Greiner, D L

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  8. Gromada, J

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

H

  1. Harrison, L C

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  2. Harrold, J

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  3. Heath, V L

    • Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes November 1999 48:2157-2165; doi:10.2337/diabetes.48.11.2157

  4. Holmgren, J

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

  5. Hutchings, P

    • Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes November 1999 48:2157-2165; doi:10.2337/diabetes.48.11.2157

  6. Høy, M

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

K

  1. Kahn, C R

    • Insulin signaling in insulin receptor substrate (IRS)-1-deficient brown adipocytes: requirement of IRS-1 for lipid synthesis. Diabetes November 1999 48:2122-2131; doi:10.2337/diabetes.48.11.2122

  2. Kelly, D J

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  3. Krolewski, A S

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

L

  1. Lee, D W

    • Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes November 1999 48:2204-2209; doi:10.2337/diabetes.48.11.2204

  2. Leif, J

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  3. Leinung, M C

    • Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes November 1999 48:2204-2209; doi:10.2337/diabetes.48.11.2204

  4. Leiter, E H

    • Resistance of ALR/Lt islets to free radical-mediated diabetogenic stress is inherited as a dominant trait. Diabetes November 1999 48:2189-2196; doi:10.2337/diabetes.48.11.2189

  5. Lelièvre-Pégorier, M

    • Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes November 1999 48:2240-2245; doi:10.2337/diabetes.48.11.2240

M

  1. Martin, A M

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  2. Mason, D W

    • Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes November 1999 48:2157-2165; doi:10.2337/diabetes.48.11.2157

  3. Mathews, C E

    • Resistance of ALR/Lt islets to free radical-mediated diabetogenic stress is inherited as a dominant trait. Diabetes November 1999 48:2189-2196; doi:10.2337/diabetes.48.11.2189

  4. Maxson, M N

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  5. Mazzanti, L

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  6. McCaul, K

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  7. Merlet-Bénichou, C

    • Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes November 1999 48:2240-2245; doi:10.2337/diabetes.48.11.2240

  8. Mordes, J P

    • Diabetes-prone and diabetes-resistant BB rats share a common major diabetes susceptibility locus, iddm4: additional evidence for a "universal autoimmunity locus" on rat chromosome 4. Diabetes November 1999 48:2138-2144; doi:10.2337/diabetes.48.11.2138

  9. Moretti, N

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  10. Motheral, T

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  11. Mulgrew, C

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

O

  1. Olsen, H L

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

P

  1. Pamplona, R

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

  2. Plengvidhya, N

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

  3. Ploix, C

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

  4. Poehlman, E T

    • Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes November 1999 48:2210-2214; doi:10.2337/diabetes.48.11.2210

  5. Polansky, M

    • Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes November 1999 48:2182-2188; doi:10.2337/diabetes.48.11.2182

  6. Pollard, A

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  7. Portero-Otín, M

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

  8. Poulsen, C R

    • Multiple sites of purinergic control of insulin secretion in mouse pancreatic beta-cells. Diabetes November 1999 48:2171-2181; doi:10.2337/diabetes.48.11.2171

  9. Powell, T

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  10. Prat, J

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

  11. Pratley, R E

    • Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes November 1999 48:2197-2203; doi:10.2337/diabetes.48.11.2197

R

  1. Rabini, R A

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  2. Redondo, M J

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  3. Rewers, M

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  4. Rich, S S

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

  5. Rizkalla, B

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  6. Robbins, P D

    • Targeting autoimmune diabetes with gene therapy. Diabetes November 1999 48:2107-2121; doi:10.2337/diabetes.48.11.2107

  7. Rudert, W A

    • Targeting autoimmune diabetes with gene therapy. Diabetes November 1999 48:2107-2121; doi:10.2337/diabetes.48.11.2107

  8. Ruiz, M C

    • Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes November 1999 48:2215-2220; doi:10.2337/diabetes.48.11.2215

S

  1. Salvolini, E

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  2. Stacker, S A

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

  3. Staffolani, R

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  4. Steele, C

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  5. Stephens, E

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  6. Suprenant, M E

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

T

  1. Tadayyon, M

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  2. Tait, B

    • Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes November 1999 48:2145-2149; doi:10.2337/diabetes.48.11.2145

  3. Tartaglia, L A

    • Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes November 1999 48:2204-2209; doi:10.2337/diabetes.48.11.2204

  4. Thivolet, C

    • Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes November 1999 48:2150-2156; doi:10.2337/diabetes.48.11.2150

  5. Trucco, M

    • Targeting autoimmune diabetes with gene therapy. Diabetes November 1999 48:2107-2121; doi:10.2337/diabetes.48.11.2107

V

  1. Valverde, A M

    • Insulin signaling in insulin receptor substrate (IRS)-1-deficient brown adipocytes: requirement of IRS-1 for lipid synthesis. Diabetes November 1999 48:2122-2131; doi:10.2337/diabetes.48.11.2122

  2. Vignini, A

    • Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes November 1999 48:2221-2228; doi:10.2337/diabetes.48.11.2221

  3. Vilar, J

    • Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes November 1999 48:2240-2245; doi:10.2337/diabetes.48.11.2240

  4. Vranes, D

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

W

  1. Warram, J H

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

  2. Wegmann, D R

    • Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. Diabetes November 1999 48:2166-2170; doi:10.2337/diabetes.48.11.2166

  3. Weyer, C

    • Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes November 1999 48:2197-2203; doi:10.2337/diabetes.48.11.2197

  4. White, D W

    • Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes November 1999 48:2204-2209; doi:10.2337/diabetes.48.11.2204

  5. Widdowson, P S

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  6. Wilding, J

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  7. Williams, G

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  8. Wilson, S

    • Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes November 1999 48:2132-2137; doi:10.2337/diabetes.48.11.2132

  9. Wogan, L T

    • Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. Diabetes November 1999 48:2246-2251; doi:10.2337/diabetes.48.11.2246

Y

  1. Youssef, S

    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes November 1999 48:2229-2239; doi:10.2337/diabetes.48.11.2229

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement